Post by Emerging Pharma Tech Ltd

𝗙𝗼𝗿 𝘆𝗲𝗮𝗿𝘀, 𝗼𝘂𝗿 𝗿𝗲𝗴𝗶𝗼𝗻'𝘀 𝗽𝗵𝗮𝗿𝗺𝗮 𝗱𝗲𝗮𝗹𝘀 𝗵𝗮𝘃𝗲 𝗹𝗶𝘃𝗲𝗱 𝗶𝗻 𝘀𝗰𝗮𝘁𝘁𝗲𝗿𝗲𝗱 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲𝘀.  𝗡𝗼𝘁 𝗮𝗻𝘆𝗺𝗼𝗿𝗲. A Korean diabetes drug entering eight Middle East and North Africa markets. A US cancer immunotherapy reaching Saudi patients through a local partner. A global manufacturer handing its Saudi plant to a homegrown champion — all in just the past few weeks. Each one a signal about where our market is heading. But these announcements sit scattered across dozens of outlets, in different languages, published once and forgotten. Nobody brings them together. Nobody explains what they actually mean. 𝗦𝗼 𝘄𝗲 𝗱𝗶𝗱. Introducing the 𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝗣𝗵𝗮𝗿𝗺𝗮 𝗧𝗲𝗰𝗵 𝗗𝗲𝗮𝗹 𝗧𝗿𝗮𝗰𝗸𝗲𝗿 — a first for our region. One place that: 🔍 Scans the market and consolidates every announced pharma deal touching our emerging markets 🧠 Sheds light on the strategy behind each one — the "why it matters," not just the headline 🤝 Is built together with industry experts who read these markets from the inside ➡️ No more chasing scattered news. One tracker. The full picture. The strategic lens. And the part we care about most: 𝘁𝗵𝗶𝘀 𝗶𝘀 #𝙁𝙧𝙚𝙚 𝗳𝗼𝗿 𝗼𝘂𝗿 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆. We'd love our network to help shape it. 📌📌𝙎𝙥𝙤𝙩𝙩𝙚𝙙 𝙖 𝙙𝙚𝙖𝙡 𝙬𝙤𝙧𝙩𝙝 𝙝𝙞𝙜𝙝𝙡𝙞𝙜𝙝𝙩𝙞𝙣𝙜? 𝙎𝙚𝙣𝙙 𝙞𝙩 𝙩𝙤 𝙪𝙨 𝙞𝙣 𝙖 𝙢𝙚𝙨𝙨𝙖𝙜𝙚 𝙤𝙣 𝙩𝙝𝙞𝙨 𝙥𝙖𝙜𝙚 , 𝙬𝙚'𝙡𝙡 𝙫𝙚𝙧𝙞𝙛𝙮 𝙞𝙩, 𝙚𝙣𝙧𝙞𝙘𝙝 𝙞𝙩, 𝙖𝙣𝙙 𝙖𝙙𝙙 𝙞𝙩, 𝙨𝙤 𝙩𝙝𝙚 𝙬𝙝𝙤𝙡𝙚 𝙘𝙤𝙢𝙢𝙪𝙣𝙞𝙩𝙮 𝙗𝙚𝙣𝙚𝙛𝙞𝙩𝙨. If this is useful to you, share it with your network. The more we each contribute what we see, the sharper the picture becomes for all of us. 🌍 📌 Explore the tracker — link in the first comment. #Pharma #EmergingMarkets #MENA #GCC #PharmaDeals #MarketIntelligence #BusinessDevelopment #Licensing #Pharmaceuticals #HealthcareMEA #Vision2030 #DealTracker